T2w images with overlays of lesion boundaries, DWI-derived ADC, DCE-derived 𝐾𝑡𝑟𝑎𝑛𝑠, and CDI𝑠 for six patient cases. (a, b) Two patients with csPCa in the PZ. (c, d) Two patients with csPCa in the TZ. (e) A patient with csPCa in the PZ and insPCa in the TZ. (f) A patient with csPCa in the AS and insPCa in the PZ.

March 28, 2022 — A new form of magnetic resonance imaging (MRI) that makes cancerous tissue glow in medical images could help doctors more accurately detect and track the progression of cancer over time.

The innovation, developed by researchers at the University of Waterloo, creates images in which cancerous tissue appears to light up compared to healthy tissue, making it easier to see.

"Our studies show this new technology has promising potential to improve cancer screening, prognosis and treatment planning," said Alexander Wong, Canada Research Chair in Artificial Intelligence and Medical Imaging and a professor of systems design engineering at Waterloo.

Irregular packing of cells leads to differences in the way water molecules move in cancerous tissue compared to healthy tissue. The new technology, called synthetic correlated diffusion imaging, highlights these differences by capturing, synthesizing and mixing MRI signals at different gradient pulse strengths and timings.

In the largest study of its kind, the researchers collaborated with medical experts at the Lunenfeld-Tanenbaum Research Institute, several Toronto hospitals and the Ontario Institute for Cancer Research to apply the technology to a cohort of 200 patients with prostate cancer.

Compared to standard MRI techniques, synthetic correlated diffusion imaging was better at delineating significant cancerous tissue, making it a potentially powerful tool for doctors and radiologists.

"Prostate cancer is the second most common cancer in men worldwide and the most frequently diagnosed cancer among men in more developed countries," said Wong, also a director of the Vision and Image Processing (VIP) Lab at Waterloo. "That's why we targeted it first in our research.

"We also have very promising results for breast cancer screening, detection, and treatment planning. This could be a game-changer for many kinds of cancer imaging and clinical decision support."

The core research team also included Hayden Gunraj and Vignesh Sivan, engineering graduate students at Waterloo, and Dr. Masoom Haider of the Lunenfeld-Tanenbaum Research Institute. 

Their paper, Synthetic correlated diffusion imaging hyperintensity delineates clinically significant prostate cancer, appears in the journal Scientific Reports.

For more information: www.uwaterloo.ca


Related Content

News | Artificial Intelligence

March 1, 2024 — Royal Philips, a global leader in health technology, and magnetic resonance imaging (MRI) software ...

Time March 01, 2024
arrow
News | FDA

March 1, 2024 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time March 01, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | Cardiac Imaging

February 12, 2024 — According to the American Journal of Roentgenology (AJR), free-breathing cine-deep learning (DL) may ...

Time February 12, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | Interventional Radiology

February 6, 2024 — RenovoRx, Inc., a clinical-stage biopharmaceutical company developing novel precision oncology ...

Time February 06, 2024
arrow
News | Treatment Planning

February 2, 2024 — RaySearch Laboratories announced that the number of radiotherapy centers that have chosen RayStation ...

Time February 02, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

It's a new year, and as another month comes to a close, ITN takes a look at the Top 10 most-read pieces of content from ...

Time February 01, 2024
arrow
News | FDA

January 30, 2024 — IceCure Medical Ltd. has announced the U.S. Food and Drug Administration (FDA) has responded ...

Time January 30, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Did you know that Imaging Technology News (ITN) maintains more than 40 comparison charts of product specifications from ...

Time January 29, 2024
arrow
Subscribe Now